FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $2,147,798 | -56.3% | 212,864 | -2.9% | 0.12% | -56.8% |
Q3 2022 | $4,911,000 | -27.4% | 219,146 | -19.7% | 0.28% | -12.8% |
Q2 2022 | $6,766,000 | -29.0% | 273,033 | +11.0% | 0.33% | -13.9% |
Q1 2022 | $9,534,000 | -34.9% | 245,916 | -1.7% | 0.38% | -26.9% |
Q4 2021 | $14,640,000 | -5.3% | 250,212 | -4.0% | 0.52% | -8.9% |
Q3 2021 | $15,455,000 | -46.9% | 260,756 | -22.3% | 0.57% | -44.8% |
Q2 2021 | $29,112,000 | -8.1% | 335,427 | -12.7% | 1.04% | +0.2% |
Q1 2021 | $31,691,000 | -10.0% | 384,362 | -0.8% | 1.03% | -16.6% |
Q4 2020 | $35,220,000 | +169.6% | 387,327 | +18.5% | 1.24% | +135.6% |
Q3 2020 | $13,064,000 | – | 326,844 | – | 0.53% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |